Clinical trial
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)
NCT00350779 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00350779 |
|---|---|
| Title | Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) |
| Official title | A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and a PPARg Agonist |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | sitagliptin, Comparator: Placebo, rosiglitazone, metformin, glipizide |
| Enrollment | 262 |
| Start date | Jun 12, 2006 |
| Primary completion | Sep 25, 2007 |
| Completion | Jun 11, 2008 |
| First posted | Jul 11, 2006 |
| Last update posted | May 12, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: